Multiplexed Tumor-Associated Autoantibody-Based Blood Test for Non-Small Cell Lung Cancer Detection

Strategic Insights -

A new study published in Clinical Cancer Research has detailed the development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer (NSCLC). According to the study, NSCLC has an overall 5-year survival rate, and a convenient serum assay capable of identifying patients with NSCLC may provide an ideal diagnostic measure to complement computed tomography-based screening protocols.

Key Takeaways:

  • The study used a standard immunoproteomic method to assess differences in circulating autoantibodies among lung adenocarcinoma patients relative to cancer-free controls, identifying 16 autoantibodies differentially expressed in NSCLC versus control serum.
  • Thirteen of the 25 analytes tested showed statistical significance (Mann-Whitney p-value ≤ 0.05), and the researchers concluded that a combination of biomarkers could be used to classify patient disease status.
  • The study used a multiplexed assay to evaluate a second patient cohort composed of four discrete populations, including NSCLC, chronic obstructive pulmonary disorder (COPD)/asthma, nonmalignant lung nodule, and 'normal' controls.
  • The researchers found that the biomarker discovery efforts yielded a convenient algorithm for classifying patient disease status and developing a tool for identifying early-stage NSCLC.
  • E.C. Farlow and colleagues published the results of their research in Clinical Cancer Research, highlighting the need for population-based validation studies to assign the true value of this tool for identifying early-stage NSCLC.

Statistics:

  • 5-year survival rate for NSCLC:
  • 16 autoantibodies differentially expressed in NSCLC versus control serum
  • 13 analytes showed statistical significance (Mann-Whitney p-value ≤ 0.05)
  • Patient cohort: 4 discrete populations, including 117 NSCLC, 30 COPD/asthma, 13 nonmalignant lung nodule, and 31 'normal' controls

Sources:

  • Farlow, E.C., et al. (2010). Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clinical Cancer Research, 16(13), 3452-3462.